Michael Horn

Michael Horn supports the National Institute on Drug Abuse (NIDA) in advancing scientific research on substance use disorders through strategic procurement of specialized scientific and technical services. He manages a portfolio of research-focused acquisitions that enable cutting-edge neurobiological, behavioral, and clinical investigations, ensuring alignment with NIDA’s mission to translate laboratory discoveries into public health applications. His acquisitions typically involve complex research instrumentation, biotechnology R&D, and professional scientific consulting services, often structured as cost-reimbursement contracts to accommodate long-term, high-risk scientific endeavors. Horn maintains strong working relationships with leading academic research institutions, including McLean Hospital Corporation, the University of Maryland Baltimore, the University of Miami, the University of Pittsburgh, and the Icahn School of Medicine at Mount Sinai. These partnerships reflect a preference for mission-aligned academic research centers with demonstrated expertise in addiction science, neuroimaging, and translational clinical trials. His contracting approach emphasizes collaboration with institutions possessing robust institutional review boards, clinical trial infrastructure, and federally funded research capabilities. His procurement patterns show a strong emphasis on open competition, with 83.9% of awards issued without set-asides, reflecting the technical specificity and scale required for high-impact research. However, he consistently allocates 16.1% of opportunities to total small business set-asides under FAR 19.5, supporting qualified small firms with niche capabilities in analytical instrumentation and scientific consulting. Horn’s primary procurement focus lies in NAICS 334516 (analytical laboratory instrument manufacturing) and 334510 (electromedical and electrotherapeutic apparatus), indicating a heavy reliance on advanced neuroimaging, biosensing, and physiological monitoring equipment. He also frequently procures services under 541990 and 541714, underscoring expertise in biotechnology R&D and specialized scientific consulting that supports data-driven addiction research and biomarker discovery.